ArticleBMC pregnancy and childbirth2026
FABP4 is highly expressed in preeclamptic placentas and regulates trophoblast lipid metabolism, mitochondrial function, and oxidative stress in vitro.
Article in BMC pregnancy and childbirth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- FABP4 as an immunometabolic hub in preeclampsia: from maternal-fetal interface to systemic inflammation.Frontiers in immunology · 2026Review
- Molecular mechanisms underlying fetal bovine serum-induced developmental delay in mouse embryos: a data-independent acquisition (DIA)-based proteomics study.Frontiers in molecular biosciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivePreeclampsia (PE) is a pregnancy-specific hypertensive disorder characterized by abnormal placental development and systemic endothelial dysfunction. Previous studies have suggested that fatty acid binding protein 4 (FABP4) is involved in lipid metabolism and oxidative stress regulation in various metabolic and cardiovascular diseases. However, its specific role and underlying mechanisms in PE, particularly in trophoblast function and mitochondrial homeostasis, remain unclear. This study aims to investigate the role of FABP4 in the pathogenesis of PE by exploring its effects on trophoblast cell function and mitochondrial oxidative stress through regulating lipid metabolism.
methodsPlacental tissues were collected from 25 PE patients and 21 healthy pregnant women to detect FABP4 expression using qRT-PCR. In vitro experiments were conducted on HTR-8/SVneo trophoblast cells. FABP4 was silenced by siRNA (si267) or inhibited by BMS309403. Cell proliferation was assessed via CCK-8 and EdU assays. RNA sequencing was performed to analyze related pathways. Free fatty acid (FFA) levels, reactive oxygen species (ROS) production, mitochondrial membrane potential, and ATP content were measured to evaluate lipid metabolism, oxidative stress, and mitochondrial function. Statistical analyses were done using t-test and one-way ANOVA.
resultsFABP4 expression was significantly higher in placental tissues of PE patients compared to controls. Both FABP4 inhibitor and siRNA knockdown suppressed HTR-8/SVneo cell proliferation. Transcriptomic analysis identified that FABP4 was enriched in pathways related to lipid metabolism (e.g., Lipid and atherosclerosis) and mitochondrial function, with key genes (e.g., PPARγ) showing differential expression. FABP4 inhibition or silencing reduced intracellular cytosolic FFA levels, increased ROS production, decreased mitochondrial membrane potential, and lowered ATP content.
conclusionFABP4 mRNA expression is elevated in placentas from preeclamptic patients. In vitro, reduction of FABP4 impairs trophoblast proliferation, which is associated with disrupted cytosolic FFA metabolism, subsequent mitochondrial dysfunction (decreased membrane potential, reduced ATP), and increased oxidative stress (elevated ROS). These findings suggest FABP4-related pathways may be involved in placental lipid handling and mitochondrial homeostasis; however, since this study only detected FABP4 mRNA (not protein) and used in vitro models, additional protein-level validation and in vivo studies (e.g., PE animal models) are required to establish causality and evaluate therapeutic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.